Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells to Augment Single or Double Myeloablative Cord Blood Transplantation in Patients With Hematologic Malignancies.

Next Previous
Trial Profile

Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells to Augment Single or Double Myeloablative Cord Blood Transplantation in Patients With Hematologic Malignancies.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dilanubicel (Primary) ; Ciclosporin; Cyclophosphamide; Fludarabine; Mycophenolate mofetil; Mycophenolate mofetil
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors Nohla Therapeutics

    • Most Recent Events

    • 16 Jul 2018 According to a Nohla Therapeutics media release, the U.S. Food and Drug Administration (FDA) has granted dilanubicel (NLA101), Orphan Drug Designation for reduction of morbidity and mortality associated with hematopoietic stem cell transplant (HSCT). This designation was supported by the results of this study.
    • 15 Jun 2018 Results (5 years) presented in a Nohla Therapeutics media release.
    • 15 Jun 2018 According to a Nohla Therapeutics media release, long-term follow-up data from this study were presented at the 23rd Congress of European Hematology Association Annual Conference.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top